Top

Published in:

01-04-2014 | Research Article

Dextran-functionalized magnetic fluid mediating magnetohyperthermia for treatment of Ehrlich-solid-tumor-bearing mice: toxicological and histopathological evaluations

Authors: Ana Luisa Miranda-Vilela, Kelly Reis Yamamoto, Kely Lopes Caiado Miranda, Breno Noronha Matos, Marcos Célio de Almeida, João Paulo Figueiró Longo, José de Souza Filho, Juliana Menezes Soares Fernandes, Patrícia Pommé Confessori Sartoratto, Zulmira Guerrero Marques Lacava

Published in: Tumor Biology | Issue 4/2014

Abstract

Dextran-functionalized maghemite fluid (DexMF) has been tested to treat Ehrlich-solid-tumor-bearing mice, evidencing its potential use in mediating magnetohyperthermia in breast cancer treatment. However, although magnetic nanoparticles tend to accumulate in tumor tissues, part of the nanomaterial can reach the blood stream, and then the organism. The aim of this study was to investigate the acute systemic effects of the intratumoral injection of DexMF mediating magnetohyperthermia in the treatment of an advanced clinical Ehrlich-solid-tumor, assessed through histopathological analyses of liver, kidneys, heart and spleen, comet assay, micronucleus test, hemogram, and serum levels of bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, creatinine, and urea. The tumor’s histopathology and morphometry were used to assess its aggressiveness and regression. DexMF mediating hyperthermia was effective in containing tumor aggressiveness and in inducing tumor regression, besides showing no toxic effects. Its physical characteristics also suggest that it is safe to use in other biomedical applications.

World Health Organization (WHO). Breast Cancer Awareness Month in October. http://www.who.int/cancer/events/breast_cancer_month/en/. Accessed April 22, 2013 2013.

Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–30.PubMedCrossRef

Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171–92.PubMedCrossRef

Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy. Artif Cells Blood Substit Immobil Biotechnol. 2010;38(5):230–49. doi:10.3109/10731199.2010.494578.PubMedCrossRef

Verrill M. Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer. 2009;101(S1):S2–5.PubMedCentralPubMedCrossRef

Rastogi A. Nanooncology: The Breast Cancer Story. UTMJ. 2011;88(3):190–4.

Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133–40. doi:10.1016/s1470-2045(00)00254-0.PubMedCrossRef

Carneiro MLB, Peixoto R, Joanitti G, Oliveira R, Telles L, Miranda-Vilela AL, et al. Antitumor effect and toxicity of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles in mice bearing breast cancer. J Nanobiotechnol. 2013;11(1):4.CrossRef

Miranda-Vilela AL, Peixoto RCA, Longo JPF, e Cintra DOS, Portilho FA, Miranda KLC, et al. Dextran-Functionalized Magnetic Fluid Mediating Magnetohyperthermia Combined with Preventive Antioxidant Pequi-Oil Supplementation: Potential Use Against Cancer. J Biomed Nanotechnol. 2013;9(7):1261–71. doi:10.1166/jbn.2013.1616.PubMedCrossRef

10.

Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2003;36:R198–206.CrossRef

11.

Tartaj P, Morales MP, Veintemillas-Verdaguer S, González-Carreño T, Serna CJ. The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2003;36(13):R182.CrossRef

12.

Ren C. Nanotechnology and the New Age of Cancer Treatment. The National High School Journal of Science. 2012. http://nhsjs.com/2012/nanotechnology-and-the-new-age-of-cancer-treatment. Accessed April 22 2013.

13.

O’Grady K. Biomedical applications of magnetic nanoparticles. J 703 Phys D: Appl Phys. 2002;36(13). doi:10.1088/0022-3727/36/13/701.

14.

Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int J Nanomedicine. 2011;6:591–603.PubMedCentralPubMed

15.

Portilho FA, Estevanato LLC, Miranda-Vilela AL, Almeida-Santos MFM, de Oliveira-Cavalcanti CE, Lacava BM, et al. Investigation of a magnetohyperthermia system efficacy. J Appl Phys. 2011;109:07B307.CrossRef

16.

Sarfati G, Dvir T, Elkabets M, Apte RN, Cohen S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials. 2011;32(1):152–61.PubMedCrossRef

17.

Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2007;15(1):3–12.PubMedCrossRef

18.

Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2(3):22–32. doi:10.1016/S1748-0132(07)70084-1.CrossRef

19.

Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113(7):823–39.PubMedCentralPubMedCrossRef

20.

Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 1981;17(2):1247–8. doi:10.1109/tmag.1981.1061188.CrossRef

21.

Miranda-Vilela AL, Portilho FA, de Araujo VG, Estevanato LL, Mezzomo BP, Almeida Santos MF, et al. The protective effects of nutritional antioxidant therapy on Ehrlich solid tumor-bearing mice depend on the type of antioxidant therapy chosen: histology, genotoxicity and hematology evaluations. J Nutr Biochem. 2011;22(11):1091–8. doi:10.1016/j.jnutbio.2010.09.009.PubMedCrossRef

22.

American Veterinary Medical Association (AVMA). AVMA Guidelines on Euthanasia. 2007. https://www.avma.org/KB/Policies/Documents/euthanasia.pdf. Accessed August 11, 2012.

23.

Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res. 1998;89(4):463–9.PubMedCrossRef

24.

Singh N, McCoy M, Tice R, Scheneider E. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184–91.PubMedCrossRef

25.

Estevanato L, Cintra D, Baldini N, Portilho F, Barbosa L, Martins O, et al. Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system. Int J Nanomedicine. 2011;6:1709–17. doi:10.2147/IJN.S21323.PubMedCentralPubMedCrossRef

26.

Estevanato LL, Lacava LM, Carvalho LC, Azevedo RB, Silva O, Pelegrini F, et al. Long-term biodistribution and biocompatibility investigation of dextran-coated magnetite nanoparticle using mice as the animal model. J Biomed Nanotechnol. 2011;8(2):301–8.CrossRef

27.

Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63(1–2):24–46. doi:10.1016/j.addr.2010.05.006.PubMedCrossRef

28.

Berry CC. Progress in functionalization of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2009;42(22):224003. 9pp.CrossRef

29.

Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: From injection site to site of action. Nano Today. 2012;7(6):606–18. doi:10.1016/j.nantod.2012.10.010.PubMedCentralPubMedCrossRef

30.

Cho W-S, Thielbeer F, Duffin R, Johansson EMV, Megson IL, MacNee W et al. Surface functionalization affects the zeta potential, coronal stability and membranolytic activity of polymeric nanoparticles. Nanotoxicology. 2013; Ahead of Print:1–10. doi:10.3109/17435390.2013.773465.

31.

Patil S, Sandberg A, Heckert E, Self W, Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28(31):4600–7. doi:10.1016/j.biomaterials.2007.07.029.PubMedCentralPubMedCrossRef

32.

Souris JS, Lee C-H, Cheng S-H, Chen C-T, Yang C-S, Ho J-aA, et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials. 2010;31(21):5564–74. doi:10.1016/j.biomaterials.2010.03.048.PubMedCentralPubMedCrossRef

33.

Stewart HL, Snell KC, Dunham LJ, Schylen SM. Transplantable and Transmissible Tumors of Animals: Atlas of Tumor Pathology. Washington: Armed Fource Institute of Pathology; 1959.

34.

Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine. 2005;1(1):22–30.PubMedCrossRef

35.

Everds NE. Hematology of the Laboratory Mouse. In: Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, editors. The Mouse in Biomedical Research: Normative Biology, Husbandry, and Models. San Diego: Elsevier; 2007. p. 133–70.CrossRef

36.

Mitruka BM, Rawnsley HM. Clinical, Biochemical and Haematological Reference Values in Normal Experimental Animals. New York: Masson Pub; 1977.

37.

Viana FAB. Guia terapêutico veterinário. 2nd ed. Gráfica Editora Cem: Minas Gerais; 2007.

38.

Organisation for Economic Co-operation and Development (OECD). OECD guideline for the testing of chemicals: Mammalian erythrocyte micronucleus test. 2012. http://www.oecd.org/env/ehs/testing/Draft%20TG%20474.pdf. Accessed May 04, 2013 2013.

39.

Quimby FW, Luong RH. Clinical Chemistry of the Laboratory Mouse. In: Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, editors. The Mouse in Biomedical Research: Normative Biology, Husbandry, and Models. San Diego: Elsevier; 2007. p. 171–216.CrossRef

40.

Sutherland RJ. Biochemical evaluation of the hepatobiliary system in dogs and cats. Vet Clin N Am Small Anim Pract. 1989;19(5):899–927.

41.

Thrall MA, Baker DC, Campbell TW, DeNicola D, Fettman MJ, Lassen ED, et al. Hematologia e Bioquímica Clínica Veterinária. 1st Edition ed. São Paulo: Editora Roca; 2007.

42.

Miras-Parra FJ, Parra-Ruiz J, Gómez-Morales M, Gómez-Jiménez FJ, de la Higuera-Torres-Puchol J. Inflammatory Pseudotumor of Lymph Nodes with Focal Infiltration in Liver and Spleen. Dig Dis Sci. 2003;48(10):2003–4.PubMedCrossRef

43.

Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci. 1980;12(1):1–58.PubMedCrossRef

44.

Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263–355.PubMedCrossRef

Title: Dextran-functionalized magnetic fluid mediating magnetohyperthermia for treatment of Ehrlich-solid-tumor-bearing mice: toxicological and histopathological evaluations
Authors: Ana Luisa Miranda-Vilela
Kelly Reis Yamamoto
Kely Lopes Caiado Miranda
Breno Noronha Matos
Marcos Célio de Almeida
João Paulo Figueiró Longo
José de Souza Filho
Juliana Menezes Soares Fernandes
Patrícia Pommé Confessori Sartoratto
Zulmira Guerrero Marques Lacava
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1447-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients

d-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells

Association between interleukin-4 -590C > T polymorphism and non-Hodgkin’s lymphoma risk

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer